Jan 31, 2015 at 14:23 | Source: CNBC-TV18
Approval subject to divestment of one antibiotic product to avoid anticompetitive impact in the US mkt
Jan 30, 2015 at 16:52 | Source: Moneycontrol.com
Brokerage house Motilal Oswal is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target price of Rs 800, in its research report dated January 28, 2015.
Jan 30, 2015 at 16:50 | Source: Moneycontrol.com
KRChoksey is bullish on Ranbaxy Laboratories and has recommended accumulate rating on the stock with a target price of Rs 780 in its January 29, 2015 research report.
Jan 28, 2015 at 15:08 | Source: CNBC-TV18
Speaking to CNBC-TV18, Sarabjit Kaur Nangra of Angel Broking said on the bottomline, margins suffered due to forex loss. The drug maker reported a forex loss of Rs 132.6 crore versus gain of Rs 10.1 crore from a year ago period.
Jan 28, 2015 at 15:03 | Source: CNBC-TV18
CNBC-TV18's Sonia Shenoy lists out stocks that you should focus on Asian Paints, Maruti, HDFC Bank, Lupin, Tata Motors, Tata Motors DVR, Titan, Ranbaxy
Jan 28, 2015 at 14:49 | Source: Moneycontrol.com
Troubled pharmaceuticals firm Ranbaxy Laboratories consolidated posted a consolidated net loss of Rs 1,030 crore compared to Rs 159 crore in the same quarter last year. Revenues dipped to Rs 2618.8 crore, compared to Rs 2,893.9 crore YoY.
Jan 28, 2015 at 11:15 | Source: CNBC-TV18
Ranbaxy Laboratories, which will soon become a part of Sun Pharma, will announce its third quarter (October-December) earnings today. Analysts expect the quarter to be a good one due to Diovan generic (is used to treat high blood pressure).
Jan 28, 2015 at 08:23 | Source: CNBC-TV18
Bharti Airtel | Tata Motors | Idea Cellular | Yes Bank | GMR Infrastructure | Amara Raja Batteries | Titan Company | Sadbhav Engineering | Gammon Infrastructure | Larsen and Toubro | Ranbaxy Labs | Hindalco Industries | GE Shipping | Cholamandalam Investment | GHCL | Karnataka Bank and Gati are stocks, which are in the news today.
Jan 27, 2015 at 22:22 | Source: CNBC-TV18
Ranbaxy has lost out on its last big drug opportunity in the US market. The US drug regulator has denied the company 180-day exclusivity for the generic version of heart burn drug Nexium. However Archana Shukla reports that Ranbaxy's loss means good times for global rival Teva and Cipla.
Jan 27, 2015 at 14:59 | Source: CNBC-TV18
CNBC-TV18's Sonia Shenoy lists out stocks that you should focus on Maruti, Ranbaxy, BEL, Max India, HDIL, Tata Motors, Asian paints, Cipla, HDFC bank
Messages on Ranbaxy Laboratories »
News across the web »
Jan 23, 2015 at 11:54 | Source: FirstPost
Nov 07, 2014 at 12:42 | Source: Calcutta Telegraph News